|
1
|
Estimated cancer incidence, mortality and
prevalence worldwide in 2012. World Health Organization. Available
from. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
|
|
2
|
O'Shaughnessy J: Extending survival with
chemotherapy in metastatic breast cancer. Oncologist. 10:(Suppl 3).
S20–S29. 2005. View Article : Google Scholar
|
|
3
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju124. 2014. View Article : Google Scholar
|
|
4
|
Sharaiha RZ, Halazun KJ, Mirza F, Port JL,
Lee PC, Neugut AI, Altorki NK and Abrams JA: Elevated preoperative
neutrophil: Lymphocyte ratio as a predictor of postoperative
disease recurrence in esophageal cancer. Ann Surg Oncol.
18:3362–3369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Azab B, Bhatt VR, Phookan J, Murukutla S,
Kohn N, Terjanian T and Widmann WD: Usefulness of the
neutrophil-to-lymphocyte ratio in predicting short- and long-term
mortality in breast cancer patients. Ann Surg Oncol. 19:217–224.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen J, Deng Q, Pan Y, He B, Ying H, Sun
H, Liu X and Wang S: Prognostic value of neutrophil-to-lymphocyte
ratio in breast cancer. FEBS Open Bio. 5:502–507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noh H, Eomm M and Han A: Usefulness of
pretreatment neutrophil to lymphocyte ratio in predicting
disease-specific survival in breast cancer patients. J Breast
Cancer. 16:55–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Azab B, Shah N, Radbel J, Tan P, Bhatt V,
Vonfrolio S, Habeshy A, Picon A and Bloom S: Pretreatment
neutrophil/lymphocyte ratio is superior to platelet/lymphocyte
ratio as a predictor of long-term mortality in breast cancer
patients. Med Oncol. 30:4322013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pistelli M, De Lisa M, Ballatore Z,
Caramanti M, Pagliacci A, Battelli N, Ridolfi F, Santoni M,
Maccaroni E, Bracci R, et al: Pre-treatment neutrophil to
lymphocyte ratio may be a useful tool in predicting survival in
early triple negative breast cancer patients. BMC Cancer.
15:1952015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Edge SBBD, Compton CC, Fritz AG, Greene FL
and Trotti A: Ajcc cancer staging manual. 7th. Springer; New York:
2010
|
|
11
|
Hortobagyi GN: Treatment of breast cancer.
N Engl J Med. 339:974–984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dan J, Zhang Y, Peng Z, Huang J, Gao H, Xu
L and Chen M: Postoperative neutrophil-to-lymphocyte ratio change
predicts survival of patients with small hepatocellular carcinoma
undergoing radiofrequency ablation. PloS One. 8:e581842013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guthrie GJ, Roxburgh CS, Farhan-Alanie OM,
Horgan PG and McMillan DC: Comparison of the prognostic value of
longitudinal measurements of systemic inflammation in patients
undergoing curative resection of colorectal cancer. Br J Cancer.
109:24–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng W, Li C, Wen TF, Yan LN, Li B, Wang
WT, Yang JY and Xu MQ: Neutrophil to lymphocyte ratio changes
predict small hepatocellular carcinoma survival. J Surg Res.
192:402–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li MX, Bi XY, Li ZY, Huang Z, Han Y, Zhou
JG, Zhao JJ, Zhang YF, Zhao H and Cai JQ: Prognostic role of
glasgow prognostic score in patients with hepatocellular carcinoma:
A systematic review and meta-analysis. Medicine (Baltimore).
94:e21332015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roxburgh CS, Salmond JM, Horgan PG, Oien
KA and McMillan DC: Comparison of the prognostic value of
inflammation-based pathologic and biochemical criteria in patients
undergoing potentially curative resection for colorectal cancer.
Ann Surg. 249:788–793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi
XS, Wang XL, Deng GL and Sun X: The relationship between serum
interleukin-6 and the recurrence of hepatitis b virus related
hepatocellular carcinoma after curative resection. Medicine
(Baltimore). 94:e9412015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Proctor MJ, Horgan PG, Talwar D, Fletcher
CD, Morrison DS and McMillan DC: Optimization of the systemic
inflammation-based glasgow prognostic score: A glasgow inflammation
outcome study. Cancer. 119:2325–2332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hartman ZC, Poage GM, den Hollander P,
Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck
SG, Mills GB and Brown PH: Growth of triple-negative breast cancer
cells relies upon coordinate autocrine expression of the
proinflammatory cytokines il-6 and il-8. Cancer Res. 73:3470–3480.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiao Y, Shiue CN, Zhu J, Zhuang T, Jonsson
P, Wright AP, Zhao C and Dahlman-Wright K: Ap-1-mediated chromatin
looping regulates ZEB2 transcription: New insights into
tnfα-induced epithelial-mesenchymal transition in triple-negative
breast cancer. Oncotarget. 6:7804–7814. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsumoto H, Koo SL, Dent R, Tan PH and
Iqbal J: Role of inflammatory infiltrates in triple negative breast
cancer. J Clin Pathol. 68:506–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
